TG Therapeutics (TGTX)
40.16
-0.40 (0.99%)
Upcoming Events
Latest Headlines
Form 8-K TG THERAPEUTICS, INC. For: Jun 03
June 3, 2026 7:34 AM - SEC Filing
TG Therapeutics reports positive Phase 1 subcutaneous BRIUMVI trial results
June 3, 2026 7:30 AM - StreetInsider
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
June 3, 2026 7:30 AM - Globe NewsWire
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
June 2, 2026 7:30 AM - Globe NewsWire
TG Therapeutics publishes data showing BRIUMVI reduced MS relapses by 56.7%
June 1, 2026 7:30 AM - StreetInsider
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
June 1, 2026 7:30 AM - Globe NewsWire
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 28, 2026 7:30 AM - Globe NewsWire
Form 8-K TG THERAPEUTICS, INC. For: May 27
May 27, 2026 4:35 PM - SEC Filing
TG Therapeutics reports positive phase 3 trial for simplified BRIUMVI dosing
May 27, 2026 7:31 AM - StreetInsider
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
May 27, 2026 7:30 AM - Globe NewsWire
TG Therapeutics presents BRIUMVI data at multiple sclerosis meeting
May 26, 2026 7:30 AM - StreetInsider
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
May 26, 2026 7:30 AM - Globe NewsWire
TG Therapeutics (TGTX) PT Raised to $70 at H.C. Wainwright
May 7, 2026 7:44 AM - StreetInsider
Form 10-Q TG THERAPEUTICS, INC. For: Mar 31
May 6, 2026 5:01 PM - SEC Filing
Form 8-K TG THERAPEUTICS, INC. For: May 06
May 6, 2026 7:26 AM - SEC Filing
TG Therapeutics (TGTX) Misses Q1 EPS by 16c, raises guidance
May 6, 2026 7:07 AM - StreetInsider
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
May 6, 2026 7:00 AM - Globe NewsWire
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026 7:01 AM - BizWire
Form DEF 14A TG THERAPEUTICS, INC. For: Jun 11
April 30, 2026 4:33 PM - SEC Filing
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
April 30, 2026 7:30 AM - Globe NewsWire
Form SCHEDULE 13G TG THERAPEUTICS, INC. Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
April 29, 2026 3:57 PM - SEC Filing
TG Therapeutics presents BRIUMVI data at neurology meeting
April 22, 2026 7:32 AM - StreetInsider
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
April 22, 2026 7:30 AM - Globe NewsWire
TG Therapeutics completes enrollment for subcutaneous BRIUMVI trial
April 15, 2026 7:30 AM - StreetInsider
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
April 15, 2026 7:30 AM - Globe NewsWire
Form SCHEDULE 13G/A TG THERAPEUTICS, INC. Filed by: VANGUARD GROUP INC
March 27, 2026 1:34 PM - SEC Filing
Form 8-K TG THERAPEUTICS, INC. For: Mar 18
March 20, 2026 4:34 PM - SEC Filing
TG Therapeutics secures $500 million credit facility, expands buyback
March 19, 2026 7:30 AM - StreetInsider
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
March 19, 2026 7:30 AM - Globe NewsWire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
March 12, 2026 7:00 AM - BizWire
TG Therapeutics data shows BRIUMVI reduces relapse rates in active MS patients
March 9, 2026 7:31 AM - StreetInsider
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
March 9, 2026 7:30 AM - Globe NewsWire
Full Article List
